Replies to post #6459 on Cel Sci Corporation (CVM)

[majatamata]

http://www.outsourcing-pharma.com/Clinical-Development/Enrollment-in-study-increases-drastically-following-inVentiv-dismissal

Here is the link. Thats the first I heard of that date. Hopefully they settle before. I'm sure inVentive doesn't want to go to trial and risk bad PR and more money. Maybe they will see the light since the judge has already dismissed their motion.

[Foxwoods Man]

Thanks for the heads up on that article.

To say I am shocked just doesn't say enough....

Sooooooo....WTF happened to the "Both parties agreed to arbitration which would eliminate the need for a lengthy trial. Participants will waive their right to trial and agree to abide by the arbitrator's decision" (paraphrased)

So we haven't got a arbitrators decision because it ain't coming folks...it's trial time and it won't even start for almost another year...so prepare for dilution and an R/S which is now a necessity

Hate to be so negative but c'mon CVM....thanks for keeping us in the link.....NOT! They NEVER mention the word "arbitration" in that article...they threw out inVentiv's trial dismissal request back in August but silence from CVM...this DOES help explain the over 50% drop in share value over the last 6 months...SOMEBODY knew....just not Joe Shareholder

Sucks

From SA November 7th, 2013:

After hitting the wires just days ago, one official news note from the biotech sector appears to have not yet been properly digested by the market.

Just days ago, CEL-SCI Corporation (NYSEMKT:CVM) announced that it has initiated an arbitration claim seeking at least $50 million in damages against inVentiv Clinical, LLC (f/k/a PharmaNet, LLC and PharmaNet GmbH (f/k/a PharmaNet AG))

This arbitration case is most likely to avoid all the dramatic twists and turns inherent in patent litigation and could be settled much more quickly